Wellderly Immune Antibodies Study, a Sub-Study of Healthy Elderly Active Longevity (HEAL) Cohort

Completed

Conditions studied: Antibodies Involved in Healthy Aging

In brief

The aim of this sub-study is to determine whether healthy individuals over 90 years of age possess immune cells that are involved in protection from chronic disease. The immune system is well known to produce anti-cancer and other immune cells, called antibodies that can be beneficial to our health. In this study the investigators will evaluate the immune status of the healthy individuals over 90 years of age. The investigators will be focused on studying molecules known to be involved in cholesterol, cancer like those for prostate cancer and breast cancer, inflammatory diseases, and infectious diseases like influenza.

Key facts

Study ID

NCT01816880

Run by

Scripps Translational Science Institute

People needed

15

Starts

2012-06-01

Expected to finish

2015-05-01

Last updated by the study team

2015-10-16

Who can join

Age: 90 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 90 and over
• Gender: Male and Female
• Enrolled in the Healthy Elderly (HEAL) study prior to enrollment in this sub-study
• Eligible for Blood draw
• Be reliable, cooperative and willing to comply with all protocol-specified procedures.
• Able to understand and grant informed consent
• Be healthy or have mild medical conditions that may be associated with the normal aging process, including:
• Hypertension, well controlled with no more than 3 medications
• Osteoporosis or Osteopenia
• Osteoarthritis
• Benign Prostatic Hypertrophy
• Cataracts, Glaucoma or Macular Degeneration
• Dyslipidemia
• Hypothyroidism
• Pre-Diabetes/Impaired Fasting Glucose (fasting blood glucose 100-126 mg/dL, if known)
• Basal or Squamous Cell Carcinoma
• Individuals will be excluded if ANY of the following conditions apply:

You may not qualify if…

• Less than 90 years of age
• Currently undergoing treatment with any investigational agents or devices within 30 preceding enrollment in this study.
• Self-reported history or current diagnosis of significant chronic conditions including:
• Any Cancer (including polycythemia; excluding basal or squamous cell carcinoma
• Coronary Artery Disease, Myocardial Infarction
• Stroke or Transient Ischemic Attack (TIA)
• Deep Vein Thrombosis or Pulmonary Embolism
• Chronic Renal Disease or Hemodialysis
• Significant Auto-Immune or Inflammatory conditions such as Rheumatoid Arthritis, Lupus, Crohn's Disease, etc.
• Alzheimer's or Parkinson's Disease
• Diabetes (Hemoglobin A1C > 6.5% or fasting glucose > 126 mg/dL or is treated with insulin or oral diabetic medication
• Aortic or Cerebral Aneurysm
• Currently taking any of the following medications on a regular basis:
• Chemotherapeutic agents (ex. Tamoxifen, Doxorubicin, Mitoxantrone, bleomycin
• Anti-platelet or anticoagulant agents, not including Aspirin (ex. Clopidogrel/Plavix, Dipyridamole/Aggrenox/Persantine, Ticlopidine/Ticlid, Warfarin/Coumadin, Prasugrel, etc.)
• Cholinesterase inhibitor for Alzheimer's disease (ex. Donzepril/Aricept)
• Insulin or oral diabetic medication
• Individual has a significant medical condition which, in the investigator's opinion, may interfere with the individual's optimal participation in the study or would potentially confound interpretation of the individual's phenotype.

Where it is running

• Scripps Translational Science Institute — La Jolla, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.